Study wrapper · #434
Dulaglutide in the era of tirzepatide and semaglutide: reaffirming its role in contemporary cardiometabolic care.
Editor's note
A narrative review arguing that dulaglutide retains a place alongside newer agents. For our tracked peptides, the useful content is comparative: the authors note that tirzepatide and semaglutide deliver larger reductions in HbA1c and body weight than dulaglutide, while framing dulaglutide's distinct strength as its cardiovascular outcome data (REWIND) and accessibility. They cite SURPASS-CVOT, which established tirzepatide's non-inferiority to dulaglutide for cardiovascular outcomes. As a narrative review this is synthesis and argument, not new data, and it is explicitly written to defend dulaglutide's role, so read the framing with that intent in mind. It is a reasonable orientation to where tirzepatide and semaglutide sit on efficacy versus an older comparator, but it should not be read as a systematic or quantitative comparison. Weight it as context, not evidence.
Plain-language abstract
This is a review article, meaning the authors summarize and interpret existing studies rather than run a new one. Their argument is that dulaglutide, an older weekly diabetes injection, still has value even though newer drugs like semaglutide and tirzepatide lower blood sugar and body weight more. The authors point out that dulaglutide has strong long-term evidence for reducing heart attacks and strokes, is simple to use with no dose adjustment, and is affordable and available in lower-income countries. They also note that a large trial (SURPASS-CVOT) showed tirzepatide was not worse than dulaglutide for heart outcomes. The overall message is that these drugs can be seen as complementary options rather than one simply replacing another, with the choice depending on a patient's needs, other health conditions and cost. Because this is an opinion-oriented review, it reflects the authors' interpretation rather than new experimental findings.